Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy

Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1337-9. doi: 10.1007/s00417-014-2634-2. Epub 2014 May 1.

Authors

Pablo Hernández-Martínez¹, Rosa Dolz-Marco, Marta Alonso-Plasencia, Rodrigo Abreu-Gonzalez

Affiliation

¹ Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Spain Polytechnic Hospital La Fe, Bulevar Sur, s/n., 46026, Valencia, Spain, pablooftalmologia@yahoo.es.

PMID: 24789465
DOI: 10.1007/s00417-014-2634-2

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Choroidal Neovascularization / diagnosis
Choroidal Neovascularization / drug therapy*
Choroiditis / diagnosis
Choroiditis / drug therapy*
Drug Substitution
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Middle Aged
Ranibizumab
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
Recombinant Fusion Proteins / therapeutic use*
Subretinal Fluid*
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Young Adult

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Recombinant Fusion Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
aflibercept
Receptors, Vascular Endothelial Growth Factor
Ranibizumab